Benostat - Nanjing Sanhome Pharmaceutical c
Latest Information Update: 19 Jul 2024
At a glance
- Originator Nanjing Sanhome Pharmaceutical
- Class Antifibrotics; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 10 Jun 2024 Phase-I clinical trials in Hepatic fibrosis (unspecified route) before June 2024 (Nanjing Sanhome Pharmaceutical pipeline, June 2024)
- 10 Jun 2024 Phase-I clinical trials in Non-alcoholic steatohepatitis (unspecified route) before June 2024 (Nanjing Sanhome Pharmaceutical pipeline, June 2024)